Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody-Drug Conjugates for Acute Leukemia.
Journal: Cancers
Published: November 26, 2025
Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis.
Journal: Clinical pharmacology and therapeutics
Published: February 28, 2024
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 08, 2020
Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia.
Journal: Leukemia & lymphoma
Published: July 07, 2020
Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
Journal: Leukemia
Published: May 11, 2020
The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia.
Journal: Leukemia
Published: October 14, 2019
The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.
Journal: British journal of haematology
Published: October 10, 2019
Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission.
Journal: Bone marrow transplantation
Published: November 01, 2018
Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.
Journal: Haematologica
Published: August 18, 2018
Last Updated: 09/26/2026